Biotalks | Behind the Approval of XH001: NeoCell Bio’s AI-Powered Breakthrough in Personalized Cancer Neoantigen Vaccines

Aug 04, 2025 17:31 CST Updated 17:31

NeoCura

RNA Innovative Drug Developer

ExpectedReadReading Time: 4 minutes

Following surgical treatment, radiotherapy, and chemotherapy, in recent years, with the rapid development of high-throughput sequencing technology, multi-omics big data analysis, and artificial intelligence algorithms, tumor immunotherapy has become a research hotspot in clinical medicine. Among these, tumor vaccines based on neoantigens have quickly become an industry focus due to their precision and innovation.

In 2017, relying on years of technical accumulation in the fields of vaccine development and RNA drugs,NeoCuraOfficially entering the race for the development of tumor neoantigen vaccines. In June this year,NeoCura's Self-Developed mRNA Personalized Tumor Neoantigen Vaccine XH001 Approved by China’s National Medical Products Administration Center for Drug Evaluation to Conduct Clinical Research（Click to view more）, injecting new vitality into cancer immunotherapy in China.

AI-Driven, Building an Innovative Platform Across the Entire Chain

Neoantigens, the products of cancer cell-specific mutations, possess both high tumor specificity and individual uniqueness. Therefore, predicting and identifying neoantigens is the cornerstone of tumor vaccine development. Dr. Wang Yi, CBO of NeoCura, pointed out: "A high-quality neoantigen must meet two major criteria — it must be present on the surface of tumor cells and able to trigger a strong immune response in the body. However, in reality, only a very small number of mutations eventually become effective neoantigens."

In order to overcome this industry challenge,NeoCura Bio-Medical Technology Co., Ltd. takes AI technology as its core engine,Five core innovation platforms have been meticulously built — Big Data Collection and Analysis Platform, Fully Automatic Drug Design Platform, Drug Screening and Validation Platform, RNA Drug Platform, and AI Bioinformatics Target Mining Platform.The five major platforms form a closed loop, covering the entire process of neoantigen prediction, presentation validation, mRNA design, efficient delivery, and production technology, building up the "full-chain moat" for RNA innovative drug research and development.

At the same time, NeoCura has established research and development centers as well as production centers in Beijing, Shenzhen, and Guangzhou, forming a complete industrial chain layout that integrates R&D, production, and clinical application, providing comprehensive support for pipeline development, platform upgrades, and clinical needs.

Focusing on Tumor Treatment, R&D Achievements Demonstrate Strength

In the R&D pipeline, NeoCura focuses on the application of mRNA technology in the oncology field, forming a multi-directional product matrix that includes cancer vaccines, cancer immunomodulation, and viral vaccines. Among these, the progress of the mRNA personalized neoantigen cancer vaccine XH001 is particularly noteworthy.

In March 2025, the IND application for XH001 was accepted by the Center for Drug Evaluation of the National Medical Products Administration; in June of the same year, the application was officially approved. This milestone marks China's advancement into a new phase of precision and intelligence in the field of cancer immunotherapy.

It is reported that,XH001 vaccine integrates the unique tumor cell mutation profile and HLA (human leukocyte antigen) typing data of patients,Customized personalized neoantigen vaccines with corresponding codes to activate tumor-specific T cells and precisely eliminate residual tumor cells.，reduce the risk of recurrence from the source.

In addition to personalized precision treatment, andCompared with traditional postoperative adjuvant treatment methods,XH001 can establish long-lasting immune memory in the human body, providing patients with prolonged protection.

With its outstanding performance in AI technology, a robust R&D pipeline, and exceptional innovation capabilities, NeoCura has successively received numerous prestigious awards such as "TOP 100 in China's Innovative Pharmaceuticals and Biologics List" and "2023 Fortune China’s Most Socially Influential Startups." These honors not only represent high recognition of NeoCura's past achievements but also serve as a motivating force driving the company forward. Dr. Wang YiSaid, "The current tumor neoantigen vaccines still belong to an emerging treatment field. Apart from rapidly advancing its existing pipeline to the clinical stage, NeoCura will also continue to expand and innovate its technology platform in the future, enabling drugs to achieve better targeting, efficacy, and safety."

Currently,Prophylactic tumor vaccines have proven their value in HPV and HBV-related cancers. Although therapeutic vaccines still face many challenges, with advancements in personalized antigen screening technology, mRNA delivery technology, and combination immunotherapy strategies, tumor vaccines are expected to become another "breakthrough therapy" that could transform cancer treatment following immune checkpoint inhibitors.